VeniSafe Materna
Genetic insight for a safer pregnancy
VeniSafe Materna is a genetic screening test that identifies inherited variants linked to thrombophilia and other pregnancy risks - empowering you to act early and keep your journey to motherhood as carefree as possible.
Why it matters?
Why it matters?
Some genetic variants can affect how your body forms blood clots, processes nutrients, or supports the placenta – all crucial for a healthy pregnancy. Even if no symptoms are present, these variants can raise the risk of miscarriage or placental problems.
Who is it for?
Who is it for?
VeniSafe Materna is for women who are:
Already pregnant and want extra reassurance
Planning to get pregnant
Experiencing fertility issues and undergoing IVF
Facing repeated pregnancy loss or complications in the past
How it helps?
How it helps?
By detecting these variants early, VeniSafe Materna empowers your doctor to guide personalised preventive care – from simple lifestyle changes to medical treatment where needed. This helps reduce risks and improve outcomes for both you and your baby.
What does VeniSafe Materna screen for?
Factor II (prothrombin, rs1799963)
Raises clotting factor levels, increasing clot risk and impairing placental flow.
Factor V Leiden (rs6025)
Makes clots form more easily and is strongly linked to recurrent miscarriage.
Factor XIII (rs5985)
Can affect placental attachment, raising the chance of bleeding and loss.
PAI-1 (rs1799768)
Hampers the breakdown of clots, contributing to thrombosis.
MTHFR (rs1801133 & rs1801131)
Can elevate homocysteine and lower folate, potentially impacting implantation and fetal development.
Dr. Luka Pirnat
specialist in general surgery, angiology, and phlebology
The VeniSafe Materna test plays an important role in managing women with unexplained recurrent pregnancy loss or pregnancy complications. It enables early identification of genetic factors associated with thrombophilia, allowing for targeted prevention and safer pregnancy care. The test result is not a diagnosis but an opportunity for timely interventions that can significantly reduce risks and improve pregnancy outcomes. The selected genes in the panel (FII, FVL, FXIII, PAI-1, and MTHFR) are clinically relevant to blood clotting and pregnancy complications, which means that a gynecologist, in collaboration with a hematologist and phlebologist, can ensure appropriate and timely care for the patient.
How does the test work?
It can be done before or during pregnancy.
VeniSafe Materna is performed from a blood sample.
The report will indicate if variants of the tested genetic factors were detected or not.
Your healthcare professional will provide tailored recommendations and, if needed, preventive treatment to support a healthy pregnancy.
VeniSafe Materna is available as an add-on to your NIPT by GenePlanet test.
In that case, both analyses are performed from the same blood sample – no extra blood draw.